Strategies in human in-vitro maturation and their clinical outcome
Strategies in human in-vitro maturation and their clinical outcome
复制标题
DOI：
10.1016/s1472-6483(10)61666-5
复制
发表时间：
2005-05-01
影响因子：
4
通讯作者：
Mikkelsen, AL
中科院分区：
文献类型：
--
作者：
Mikkelsen, AL
体外成熟(IVM)的基础是卵母细胞从生发泡(GV)发育到中期11的体外成熟。处理未成熟卵母细胞的经验主要来自两个群体。第一组是患有多囊卵巢综合征的妇女，她们在辅助生殖中对外源性促性腺激素的刺激非常敏感，并有很大的风险患上卵巢过度刺激综合征(OHSS)。第二组是卵巢正常的定期周期妇女，由于严重的男性不育而被转介进行试管受精。在这两组中，未成熟卵母细胞分别在未刺激周期和用人绒毛膜促性腺激素或卵泡刺激素(FSH)预充后抽吸。临床妊娠率为每次抽吸24%。IVM后出生的孩子看起来很健康。这些数据综合起来表明，在未来，在选定的患者中，未成熟卵母细胞获取结合体外受精可以取代传统的体外受精。
The basis of in-vitro maturation (IVM) is the maturing in vitro of oocytes from the germinal vesicle (GV) stage of development to the metaphase 11 stage. Experience in handling immature oocytes has been obtained from two main groups. The first group is women suffering from polycystic ovarian syndrome, who are extremely sensitive to stimulation with exogenous gonadotrophins in assisted reproduction, and have a significant risk of developing ovarian hyperstimulation syndrome (OHSS). The second group is regular cycling women with normal ovaries referred for IVF due to severe male infertility. In both groups, aspiration of immature oocytes has been performed in unstimulated cycles and after priming with human chorionic gonadotrophin or FSH respectively. Clinical pregnancy rates of 24% per aspiration have been obtained. Children born after IVM appear to be healthy. These data, taken together, suggest that in future, immature oocyte retrieval combined with IVM could replace conventional IVF in selected patients.